Free Trial

Viridian Therapeutics (VRDN) Stock Forecast & Price Target

$15.61
+0.63 (+4.21%)
(As of 07/23/2024 ET)

Viridian Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Based on 12 Wall Street analysts who have issued ratings for Viridian Therapeutics in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 12 analysts, 2 have given a hold rating, and 10 have given a buy rating for VRDN.

Consensus Price Target

$32.00
105.00% Upside
High Forecast$40.00
Average Forecast$32.00
Low Forecast$20.00

According to the 12 analysts' twelve-month price targets for Viridian Therapeutics, the average price target is $32.00. The highest price target for VRDN is $40.00, while the lowest price target for VRDN is $20.00. The average price target represents a forecasted upside of 105.00% from the current price of $15.61.

TypeCurrent Forecast
7/25/23 to 7/24/24
1 Month Ago
6/25/23 to 6/24/24
3 Months Ago
4/26/23 to 4/25/24
1 Year Ago
7/25/22 to 7/25/23
Consensus Rating
Moderate Buy
Moderate Buy
Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
10 Buy rating(s)
10 Buy rating(s)
10 Buy rating(s)
12 Buy rating(s)
Hold
2 Hold rating(s)
2 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$32.00$32.00$36.60$45.20
Forecasted Upside105.00% Upside107.65% Upside90.95% Upside68.57% Upside
Get Viridian Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for VRDN and its competitors with MarketBeat's FREE daily newsletter.

VRDN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

VRDN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Viridian Therapeutics Stock vs. The Competition

TypeViridian TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.83
2.72
2.51
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside105.00% Upside3,059.01% Upside9.72% Upside
News Sentiment RatingNeutral News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
7/16/2024HC Wainwright
3 of 5 stars
 Reiterated RatingBuy ➝ Buy$27.00 ➝ $27.00+83.80%
6/11/2024Needham & Company LLC
3 of 5 stars
 Reiterated RatingBuy ➝ Buy$30.00 ➝ $30.00+134.56%
6/11/2024Wolfe Research
3 of 5 stars
 Initiated CoverageOutperform$29.00+137.32%
6/6/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$23.00+86.39%
5/9/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$36.00 ➝ $31.00+121.43%
5/9/2024LADENBURG THALM/SH SH
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Higgins
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral
5/9/2024B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
K. Patel
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral$25.00 ➝ $20.00+34.23%
2/28/2024Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$39.00 ➝ $40.00+103.98%
12/14/2023Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Outperform$35.00+81.63%
11/14/2023JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetMarket Outperform ➝ Market Outperform$42.00 ➝ $38.00+152.16%
9/13/2023Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$40.00+140.10%
8/9/2023Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$46.00 ➝ $39.00+108.00%
6/14/2023BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$46.00+73.32%
1/9/2023SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$40.00 ➝ $45.00+41.02%
12/19/2022Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$45.00+61.41%
12/16/2022Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$51.00+85.52%
8/15/2022Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$40.00 ➝ $50.00+123.41%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 04:13 AM ET.

VRDN Forecast - Frequently Asked Questions

What is Viridian Therapeutics' forecast for 2024?

According to the research reports of 12 Wall Street equities research analysts, the average twelve-month stock price forecast for Viridian Therapeutics is $32.00, with a high forecast of $40.00 and a low forecast of $20.00.

Should I buy or sell Viridian Therapeutics stock right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Viridian Therapeutics in the last twelve months. There are currently 2 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" VRDN shares.

Does Viridian Therapeutics's stock price have much upside?

According to analysts, Viridian Therapeutics's stock has a predicted upside of 106.69% based on their 12-month stock forecasts.

Has Viridian Therapeutics been downgraded by Wall Street analysts recently?

Over the previous 90 days, Viridian Therapeutics's stock had 2 downgrades by analysts.

What analysts cover Viridian Therapeutics?

Viridian Therapeutics has been rated by research analysts at B. Riley, HC Wainwright, LADENBURG THALM/SH SH, Needham & Company LLC, Oppenheimer, The Goldman Sachs Group, and Wolfe Research in the past 90 days.

Do Wall Street analysts like Viridian Therapeutics more than its competitors?

Analysts like Viridian Therapeutics more than other "medical" companies. The consensus rating score for Viridian Therapeutics is 2.83 while the average consensus rating score for "medical" companies is 2.72. Learn more on how VRDN compares to other companies.


This page (NASDAQ:VRDN) was last updated on 7/24/2024 by MarketBeat.com Staff

From Our Partners